重组人可溶性血栓调节蛋白治疗脓毒症相关凝血病的疗效与安全性:系统评价与荟萃分析
该系统评价与荟萃分析纳入3项随机对照试验共1633例脓毒症患者,评估重组人可溶性血栓调节蛋白(rhsTM)的疗效与安全性。结果显示,合并脓毒症相关凝血病(SAC)者28天死亡率更高;rhsTM可显著降低SAC患者的28天死亡率,但对无SAC者及总体人群无此效应,且未显著增加大出血风险。
要点
- SAC患者28天死亡率高于无SAC者(RR 1.32)。
- rhsTM降低SAC患者28天死亡率(RR 0.80),无SAC者未见获益。
- rhsTM与对照组大出血风险无显著差异。
核心结论
- 在脓毒症患者中,SAC与更高的28天死亡率相关。
- rhsTM可降低SAC患者的28天死亡率,但对无SAC患者无此效应。
研究设计与样本
- 系统评价与荟萃分析,检索EMBASE、MEDLINE、CENTRAL及clinicaltrial.gov的随机对照试验。
- 纳入3项比较rhsTM与安慰剂或无治疗的随机对照试验,共1633例脓毒症患者。
- 疗效结局为28天死亡率,安全性结局为大出血。
主要发现
- SAC患者28天死亡率高于无SAC患者(RR 1.32;95%CI 1.06-1.64)。
- SAC患者中rhsTM组28天死亡率低于对照组(RR 0.80;95%CI 0.65-0.98)。
- 无SAC患者中rhsTM与对照无显著差异(RR 1.17;95%CI 0.82-1.67)。
- 总体人群中rhsTM与对照无显著差异(RR 0.88;95%CI 0.74-1.04)。
- 大出血在总体人群(RR 1.25;95%CI 0.80-1.96)、SAC患者(RR 0.94;95%CI 0.45-1.95)及无SAC者(RR 2.26;95%CI 0.95-5.35)均无显著差异。
关键数值与推荐
- SAC定义依据高国际标准化比值和低血小板计数。
- 疗效结局为28天死亡率,安全性结局为大出血。
临床怎么用
- 对脓毒症患者应识别是否合并SAC,因其与更高28天死亡率相关。
- rhsTM或可考虑用于合并SAC的脓毒症患者以降低28天死亡率,但需结合出血风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy and safety of recombinant human soluble thrombomodulin (rhsTM) have not been definitively proven. The effects may depend on the presence of sepsis-associated coagulopathy (SAC). OBJECTIVES: The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of rhsTM in patients with SAC defined by high international normalized ratio and low platelet count. PATIENTS/METHODS: EMBASE, MEDLINE, CENTRAL, and clinicaltrial.gov were searched for randomized controlled trials (RCTs) comparing rhsTM with placebo or no treatment in patients with sepsis. The efficacy outcome was 28-day mortality, and the safety outcome was major bleeding. RESULTS: We included 3 RCTs with a total of 1633 patients. Twenty-eight-day mortality was higher in patients with SAC compared with those without SAC (risk ratio [RR] 1.32; 95% confidence intervals [CI], 1.06-1.64). rhsTM was associated with significantly lower 28-day mortality compared with placebo or no treatment in patients with SAC (RR 0.80; 95% CI, 0.65-0.98), but not in those without SAC (RR 1.17; 95% CI, 0.82-1.67) nor in the whole study population (RR 0.88; 95% CI, 0.74-1.04). There was no significant difference in major bleeding between rhsTM and controls in the whole population (RR 1.25; 95% CI, 0.80-1.96), patients with SAC (RR 0.94; 95% CI, 0.45-1.95), and those without SAC (RR 2.26; 95% CI, 0.95-5.35). CONCLUSIONS: In patients with sepsis, SAC is associated with higher 28-day mortality. The administration of rhsTM reduced 28-day mortality in patients with SAC, but not in those without SAC.
引用
- Valeriani E, Squizzato A, Gallo A, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: A systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32237269. doi:10.1111/jth.14812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。